Beruflich Dokumente
Kultur Dokumente
KEY SPEAKERS INCLUDE:Joan Francesc Aregall Picamal, Pharmacovigilance Country Head, Bayer William Gregory, Director, Safety and Risk Management, Pfizer Christina Strom Moller, Vice President - Patient Safety Late Development & Marketed Products, AstraZeneca Arlene Gallagher, Statistician, Epidemiologist Clinical Practice Research Datalink, MHRA Ashish Kohli, Senior Director-Established Products Regulatory Portfolio Lead EU/Aus/NZ, Pfizer Julia Appelskog, EU QPPV, Bluefish Pharmaceuticals Susanne Ramm, Head of Medical Science & Affairs, Dr. Ebeling & Assoc Andrew Cochrane, Deputy EU QPPV, Novartis Merete Schmiegelow, Sr Director - EU Regulatory Advocacy Regulatory Policies & Intelligence, Novo Nordisk Phillip Eichorn, Senior Director, Pfizer Sumit Munjal, Global Director, Pharmacovigilance & EU Region Medical Advisor - Lead Oncology Portfolio, Takeda Oncology: Millennium Pharmaceuticals Nicolas Limbos, Senior Drug Safety Scientist, Keyrus Biopharma Franziska Albrecht, Senior Pharmacovigilance Advisor, Dr. Ebeling & Assoc
Maarten Van Baelen, Medical Affairs Manager, EGA (European Generic Medicines Association) Vito Strasberger, CEO, Nanokinetik Steinar Madsen, Medical Director, Norweigen Medicines Agency Vid Stanulovic, Medical Safety Officer, Aprova David Jefferys, Sr. VP Regulatory, Eisai Pharmaceuticals Paul Dolin, Senior Director, Takeda Pharmaceuticals Caroline Pastor, Pharmacovigilance Operations Manager, Aprova Pipasha Biswas, Director & QPPV, PV & Pharmacoepidemiology, Symogen John Talbot, Senior Lecturer, Pharmacovigilance, University of Hertfordshire Deborah Layton, Principal Research Fellow, Drug Safety Research Unit (DSRU) Fiona Maini, Sr. Manager, Deloitte Consulting Joanna Hook, Associate, Bristows
6th Pharmacovigilance 2014 04th & 05th March 2014, Thistle Marble Arch Hotel, London, UK
PLATINUM SPONSOR
GOLD SPONSOR
BRONZE SPONSOR
ASSOCIATE SPONSOR
SUPPORTED BY
ORGANIZED BY
6th Pharmacovigilance 2014 04th & 05th March 2014, Thistle Marble Arch Hotel, London, UK
CONFERENCE INTRODUCTION:New European Union (EU) pharmacovigilance legislation was adopted by the European Parliament and Council of Ministers in December 2010. Many of the new provisions contained in the legislation have been effective since July 2012. It is estimated that the average spend on pharmacovigilance is 6% to 13% of a companies total R&D. From product development in clinical trials to post marketing surveillance, adverse drug reactions are monitored and safety signals investigated. The new legislation includes sweeping changes that leave industry with a lot of questions. If you want to file your product in Europe (MAA), what new PV regulatory processes do you need to put in place? Will the Pharmacovigilance System Master File be useful? And what is really meant by a Quality Management System? The Conference will bring together top pharmaceutical, biotechnology and regulatory representatives under one roof that will address the key issues of the industry. The entire program will cover the detection, analysis and prevention of adverse drug reactions. It will be studied with the help of case studies and industry experiences. 6th Pharmacovigilance 2014 is the latest in Virtue Insights series of successful pharmacovigilance events. Also it can help you control your product's lifecycle, your patient's trust, and your revenue. Hence, this conference will provide an important platform for pharmacovigilance stakeholders to discuss and share best practices in expediting pharmacovigilance development It gives me great pleasure in welcoming all of you to the Virtue Insights 6th Pharmacovigilance 2014. I wish and pray that all our efforts will be beneficial to our industries and to our country at large.
KEY THEMES DISCUSSED AT THIS CONFERENCE: Fiercest technologies, methodologies and introducing pharmacy automations on work practices of Pharmacovigilance in EU & US PRAC & European Pharmacovigilance legislation - Implementation and Beyond Updating yourself with respect to terms of legislation, policies, systems, technology, communication strategies and best practice in PV How will PV activities change with Clinical trial transformation initiative? Pharmacovigilance system master file Audit and Inspection: Realistic steps for a fruitful consequence Discover approaches for collecting, integrating and analyzing all of the safety data generated from preclinical models Exploiting the pharmacy automations and technologies for enhancement of medication safety Impact of technology learn and explore Latest developments in pharmacovigilance, drug safety and risk management to ensure safer drugs to market Improving patient care and safety in relation to use of medicines and all medical and paramedical interventions Determining the steps and strategies for enhancing quality in healthcare Signals: From detection to validation Review the use of Periodic Safety Update Reports (PSURs) post-authorisation for safety signals Legislative framework, including GVP modules Dwell ahead of regulatory developments & improving your risk management strategies in a cost effective way in EU, US Accelerating new medicine introduction in developing world & overcoming challenges Explaining how to use the data sources and observational research for effective safety analysis Be part of a major networking opportunity
WHO SHOULD ATTEND? VPs, Directors, Heads, Managers, Scientific Advisors, Consultants of: Pharmacovigilance, Pharmacoepidemiology, Pharmacogenomics, Drug/Product Safety, Drug Development, Information and Clinical Data Management, Clinical Pharmacology, Clinical Safety, Periodical safety update Reports, Risk Management, Research & Development, Quality Assurance, Patient Safety, Signal Detection, Safety Surveillance, Outcomes Research, Data Analysis, Epidemiology, Medical Affairs, Regulatory Affairs and Compliance, Information technology, Sales and Marketing
WHY SHOULD YOU ATTEND? 6th Pharmacovigilance 2014 Uniting Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management" Get more from the event, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking drinks time, meet the leading international vendors showcasing the products of tomorrow in the co-located exhibition. Expand your knowledge of the latest business models and strategies in the high-level conference. Whether you are on the branded or generic side, you cannot afford to miss this opportunity to benchmark your tactics and strategies against the industry leaders who will be the first to traverse the pathway. Devise an immediate action plan for your biosimilar prosecution and litigation strategies in light of the barriers to entry, research and development costs, and regulatory hurdles, which are balanced against an enormous potential for increased profit margins.
6th Pharmacovigilance 2014 04th & 05th March 2014, Thistle Marble Arch Hotel, London, UK
DAY ONE - 04TH MARCH 2014
08:30 Coffee and registration An opportunity to meet and to network with your conference colleagues. 09:30 Chairperson opening remarks Merete Schmiegelow, Sr Director - EU Regulatory Advocacy Regulatory Policies & Intelligence, Novo Nordisk
(http://www.linkedin.com/pub/merete-schmiegelow/6/874/127)
Sumit Munjal, Global Director, Pharmacovigilance & EU Region Medical Advisor - Lead Oncology Portfolio, Takeda Oncology: Millennium Pharmaceuticals
(http://www.linkedin.com/pub/sumit-munjal/17/400/410)
12:00 Signal Management and Continuous Benefit-Risk Assessment (CoBRA) including synergies with PSURCompilation Legislative and regulatory guidance (GVP) Strategical and systematical approach for screening of sources Linking signal detection, continuous benefit-risk assessment and Emerging Safety Issues Evaluation and validation of potential signals in practice Considerations for and consequences of potential & identified risks CoBRA reports for use with respect to PSUR compilation Quality assurance and traceability of Signal Management and CoBRA
10:20 Morning Keynote Address 2 Lessons learned from management of safety data from patient support and market research programs Overview of legal requirements Perspectives in handling of safety information Collaborations with service provider
Susanne Ramm, Head of Medical Science & Affairs, Dr. Ebeling & Assoc 12:40 - Networking luncheon - Take your discussions further & build new relationships in a relaxed & informal setting...
Merete Schmiegelow, Sr Director - EU Regulatory Advocacy Regulatory Policies & Intelligence, Novo Nordisk
(http://www.linkedin.com/pub/merete-schmiegelow/6/874/127)
Panellists: Christina Strom Moller, Vice President - Patient Safety Late Development & Marketed Products, AstraZeneca
(http://www.linkedin.com/pub/christina-strom-moller/7/954/81a)
Steinar Madsen, Medical Director, Norweigen Medicines Agency John Talbot, Senior Lecturer, Pharmacovigilance, University of Hertfordshire (http://www.linkedin.com/pub/john-talbot/31/500/b14)
6th Pharmacovigilance 2014 04th & 05th March 2014, Thistle Marble Arch Hotel, London, UK
14:40 Pharmacovigilance Systems Crisis Crises in pharmacovigilance system occur for several reasons: Audit/inspection findings probably top the list. A newly discovered safety concern for a drug frequently reveals deficiencies in the system. Or it may be just a risk identified by regulatory authorities which requires action. Whatever the cause for the crisis, the PV systems may suddenly become a hot topic and endanger a companys very existence. The question is: where to start fixing it? Shall it be new procedures? Database? Qualified personnel? Training? Regulatory consultation? Outsource or hire? Vid Stanulovic, Medical Safety Officer, Aprova
(http://www.linkedin.com/pub/vid-stanulovic/4/237/3b6)
Caroline Pastor, Pharmacovigilance Operations Manager, Aprova (http://www.linkedin.com/pub/caroline-pastor/42/89a/a0b) 15:10 Afternoon Tea/Coffee
TECHNOLOGY IMPACT
15:30 - IT solutions for Pharmacovigilance
Franziska Albrecht, Senior Pharmacovigilance Advisor, Dr. Ebeling & Assoc 10:20 Morning Keynote Address 2 The transition to the new EU RMPan industry perspective Challenges in converting existing RMPs to the new structurelessons learned Benefits and pitfalls of the new RMP structure Approaches to the new templatepain points and future directions Modularity and synergy with the PSUR/PBRER and DSUR Managing resource under the new requirementsmore RMPs, fewer updates?
16:30 - Experience with EU Risk Management Plans and how to assess their effectiveness Background to RMPs, legislation and guidance Experience with EU RMPs to date The new EU RMP Structure (GVP Module V) Risk minimisation measures and assessing their effectiveness (GVP Module XVI) Examples of measurement of effectiveness
John Talbot, Senior Lecturer, Pharmacovigilance, University of Hertfordshire (http://www.linkedin.com/pub/john-talbot/31/500/b14) 17:00 - Chairpersons closing remarks and end of conference Merete Schmiegelow, Sr Director - EU Regulatory Advocacy Regulatory Policies & Intelligence, Novo Nordisk
(http://www.linkedin.com/pub/merete-schmiegelow/6/874/127)
17:10 - 18:10 - Networking Drinks - Take your discussions further & build new relationships in a relaxed & informal setting.
6th Pharmacovigilance 2014 04th & 05th March 2014, Thistle Marble Arch Hotel, London, UK
12:00 A Researchers perspective of Risk Management Planning Fulfilling the need for innovation Understanding the local health services in practice Study design considerations Real-life case examples
Deborah Layton, Principal Research Fellow, Drug Safety Research Unit (DSRU)
12:40 - Networking luncheon - Take your discussions further & build new relationships in a relaxed & informal setting...
Moderator:
Merete Schmiegelow, Sr Director - EU Regulatory Advocacy Regulatory Policies & Intelligence, Novo Nordisk
(http://www.linkedin.com/pub/merete-schmiegelow/6/874/127)
Panellists: Ashish Kohli, Senior Director-Established Products Regulatory Portfolio Lead EU/Aus/NZ, Pfizer
(http://www.linkedin.com/pub/ashish-kohli/4/a3a/11a)
Maarten Van Baelen, Medical Affairs Manager, EGA (European Generic Medicines Association)
(http://www.linkedin.com/pub/maarten-van-baelen/4/200/544)
Arlene Gallagher, Statistician, Epidemiologist Clinical Practice Research Datalink, MHRA (http://www.linkedin.com/pub/arlenegallagher/5b/371/b82)
(http://www.linkedin.com/pub/david-jefferys/10/172/10)
14:40 - Standards for PSPs and marketing programs after an MHRA inspection History of PSPs and inspection findings Defining quality standards for marketing programs Remediation of ongoing programs Conclusions
17:00 - 17:10 Chairpersons closing remarks and end of conference & End of the 6th Pharmacovigilance 2014 Merete Schmiegelow, Sr Director - EU Regulatory Advocacy Regulatory Policies & Intelligence, Novo Nordisk
(http://www.linkedin.com/pub/merete-schmiegelow/6/874/127)
15:20 Afternoon Tea/Coffee 15:40 Practical aspects of a drug utilization PASS study Paul Dolin, Senior Director, Takeda Pharmaceuticals
(http://www.linkedin.com/pub/paul-dolin/4/439/22b)
.-4- +- 0)
!N
5%
!N
5&
!N
5'
3x2m
3x2m
x2 3m 34x m
, H
REGISTRATION DESK
, H
3x2m
3x2m
3x2m
6th Pharmacovigilance 2014 04th & 05th March 2014, Thistle Marble Arch Hotel, London, UK
RESERVATION PRICING:
Super Early Discount (Till 20th December 2013) Early Discount (21st December 2013 - 28th January 2014) Standard Pricing ( 29th January 2014) - 500 + VAT (Per Delegate) - 700 + VAT (Per Delegate) - 1000 + VAT (Per Delegate)
PAYMENT:
Please send me a VAT invoice I enclose a cheque for Please charge my card Card Number Security No Issue Date Cardholders Name Cardholders Registered Address Postcode Our purchase order no.is
8EHJKA 1 IECDJ J@
Visa Mastercard Maestro
Expiry Date
Date Signature
*=
= A - HSBC
5 HJ + @A - 40-25-27
Virtue Insight requires the full amount to be paid before the conference. Virtue Insight may refuse entry to delegates who have not paid their invoice in full.
Indemnity:
Virtue Insight reserves the right to make alterations to the conference/executive briefing content, timing, speakers or venue without notice. The event may be postponed or cancelled due to unforeseen events beyond the control of Virtue Insight. If such a situation arises, we will refund your registration fee and we will try to reschedule the event.
Fee:
The conference fee includes lunch, refreshments and conference papers provided on the day. This fee does not include travel or hotel accommodation.